ALKERMES | ALKS - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 16.62B 840M 2025-12
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
ALKERMES USD 384.5M 9.7M 2025-12
Amgen USD 9.9B 340M 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Coherus Biosciences USD 7.6M 46.54M 2025-03
Eli Lilly USD 19.3B 1.7B 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Heron Therapeutics USD 32.81M 3.21M 2024-09
Ionis Pharmaceuticals USD 203M 46M 2025-12
J&J USD 24.6B 610M 2025-12
Merck USD 16.4B 880M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 24.12M 635K 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Otsuka Holdings JPY 650.15B 12.17B 2025-12
Pfizer USD 17.58B 880M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12